Policy

Evidence Development

Background

The future of personalized medicine depends in part on the development of evidence to demonstrate the field's clinical and economic value.

To that end, in February of 2018, PMC supported a revised draft of a bill from Rep. Eric Swalwell (D-CA) that would provide for a study at the National Academy of Medicine (NAM) on the use of genetic and genomic testing to improve health care outcomes. In addition to expressing PMC's continued support for the bill, which the Coalition first voiced in a comment letter to Swalwell's office in July of 2017, the latest letter commends Swalwell for requiring that NAM consult with a diverse group of stakeholders as the Academy develops from the outset the criteria it intends to use to measure improved health outcomes.

2018

"Advancing Access to Precision Medicine Act"

2017

"Access to Precision Medicine Advancement Act"